Feature Channels: Vaccines

Filters close
Newswise: Guiding Vaccine Development with Machine Learning
Released: 10-Aug-2023 10:35 AM EDT
Guiding Vaccine Development with Machine Learning
Pacific Northwest National Laboratory

The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.

   
Newswise: New Machine-Learning Method May Aid Personalized Cancer Therapy
Released: 9-Aug-2023 11:00 AM EDT
New Machine-Learning Method May Aid Personalized Cancer Therapy
Johns Hopkins Medicine

Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response. If validated in clinical trials, the technology could help scientists overcome a major hurdle to developing personalized immunotherapies and vaccines.

   
Newswise: Community Conversations: A Jump-Start to a Healthy School Year
Released: 8-Aug-2023 11:35 AM EDT
Community Conversations: A Jump-Start to a Healthy School Year
Cedars-Sinai

Cedars-Sinai and BlackDoctor.org will host a virtual community conversation to help kick-off the back-to-school season.

Newswise: First steps towards a new vaccine for childhood ear infections
Released: 8-Aug-2023 8:25 AM EDT
First steps towards a new vaccine for childhood ear infections
University of Adelaide

University of Adelaide researchers have started work on developing a new vaccine that could help ward off painful ear infections in children. The potential vaccine is in the initial stages of development in the lab and will target one of the main types of bacteria that cause middle ear infections, a common illness among infants and young children.

Released: 4-Aug-2023 10:40 AM EDT
An adjuvanted intranasal vaccine for COVID-19 protects both young and old mice
Michigan Medicine - University of Michigan

A collaborative research effort led by the University of Michigan and the Icahn School of Medicine at Mount Sinai has resulted in a nasal vaccine adjuvant that stops COVID infection in both young and old mice.

Released: 2-Aug-2023 1:25 PM EDT
One year post-COVID-19 mass vaccination, immunization coverage is higher among those eligible for priority vaccination
University of Tsukuba

At the beginning of the mass vaccination against COVID-19 infection, the government had to determine eligibility for priority vaccination.

Newswise: Extroverts More Likely to Resist Vaccines, Study Shows
Released: 2-Aug-2023 5:00 AM EDT
Extroverts More Likely to Resist Vaccines, Study Shows
University of Texas at El Paso

Which types of personalities were more hesitant about COVID-19 vaccination during the pandemic’s peak? Extroverts — according to a new study on more than 40,000 Canadians.

   
Released: 1-Aug-2023 5:30 PM EDT
Three doses of COVID-19 vaccine leads to catch-up antibody responses among the particularly vulnerable
University of Gothenburg

Even vulnerable people, who are at risk of severe Covid-19, achieved good antibody levels after three doses of mRNA vaccine.

Released: 1-Aug-2023 9:05 AM EDT
COVID-19 Vaccines: What Parents Need to Know Now
Children's Hospital Los Angeles

The coronavirus pandemic is no longer a national emergency, but the virus that causes COVID-19 isn’t gone—and neither is the risk of getting the disease. For parents, navigating when to get their child vaccinated and knowing how to best protect their child from COVID-19 can be complicated. We spoke to Michael Smit, MD, MSPH, Hospital Epidemiologist and Medical Director of Infection Prevention and Control at Children’s Hospital Los Angeles, to get an update on the latest COVID-19 vaccine information and precautions.

Released: 31-Jul-2023 12:00 PM EDT
Duke Clinical Research Institute launches long COVID trials through NIH RECOVER Long COVID Initiative
Duke Clinical Research Institute

Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies.

Newswise: Asymptomatic infections may underlie recent rise in whooping cough
Released: 26-Jul-2023 1:35 PM EDT
Asymptomatic infections may underlie recent rise in whooping cough
La Jolla Institute for Immunology

In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.

   
Released: 25-Jul-2023 5:05 PM EDT
84% cut in Covid deaths for UK cancer patients following vaccine rollout
University of Birmingham

Cancer patients saw a significant fall in Covid-related hospitalisations and mortality following the rollout of vaccines in the first panoramic study of its kind.

Newswise: New algorithm may fuel vaccine development
Released: 25-Jul-2023 1:55 PM EDT
New algorithm may fuel vaccine development
La Jolla Institute for Immunology

Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.

   
Released: 25-Jul-2023 12:50 PM EDT
A chance to design better vaccines?
Oxford University Press

A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.

Released: 24-Jul-2023 5:35 PM EDT
Large study determines number needed to be vaccinated to prevent COVID-19 hospitalizations and ED visits
Regenstrief Institute

An analysis of real-world data from more than 1.2 million patients from health systems in four geographically dispersed states -- Indiana, Oregon, Texas and Utah -- conducted by the U.S. Centers for Disease Control and Prevention’s VISION Network, has determined both the number of adults needed to be vaccinated to prevent one COVID-19 associated hospitalization and the number needed to be vaccinated to prevent one COVID-19 associated emergency department (ED) visit.

Released: 24-Jul-2023 8:45 AM EDT
How people judge anti-vaxxers who die from COVID-19
Ohio State University

When people who publicly reject COVID-19 vaccines later die from the disease, observers have complex reactions to their fates, a new study suggests. While very few rejoice in the deaths of anti-vaxxers, some people believe those who are dogmatic against vaccines are deserving of worse outcomes – and that reaction is related to the political party affiliation and vaccination status of the person evaluating the anti-vaxxer.

   
Released: 20-Jul-2023 4:40 PM EDT
Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission
Mount Sinai Health System

The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.

Released: 18-Jul-2023 11:00 AM EDT
New MenB vaccine heralds use of genetic vaccines to combat bacterial diseases
University of Surrey

A vaccine candidate that can protect children from Meningococcal group B (MenB), which can lead to meningitis, has progressed to clinical development, according to an announcement by researchers from the University of Surrey and the University of Oxford.

Newswise: Using AI to Speed Up Vaccine Development Against Disease X
Released: 18-Jul-2023 9:00 AM EDT
Using AI to Speed Up Vaccine Development Against Disease X
Houston Methodist

CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for design of vaccines to fight diseases with pandemic potential. The project will support a consortium, led by HMRI, to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.

Released: 17-Jul-2023 3:05 PM EDT
Rural mortality rose during year two of pandemic, despite vaccines, new study finds
Boston University

BU research highlights how healthcare inequities between urban and rural areas, and vaccine skepticism, played a role in deaths related to COVID.

Newswise: Pancreatic Cancer Vaccine Plus Immunotherapy and Antibody Spark Immune System Response in Pancreatic Cancers
Released: 17-Jul-2023 10:00 AM EDT
Pancreatic Cancer Vaccine Plus Immunotherapy and Antibody Spark Immune System Response in Pancreatic Cancers
Johns Hopkins Medicine

Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.

Released: 14-Jul-2023 12:55 PM EDT
Link between oropharyngeal cancer and sexual behavior
Universität Leipzig

Human papillomavirus (HPV) is a ubiquitous virus, and most people are infected at some point in their lives. HPV can infect epithelial cells of the skin and mucosa at various sites.

Newswise: Bar-Ilan University study reveals disparity in quality of life among COVID-19 survivors from different ethnic groups
Released: 5-Jul-2023 6:50 PM EDT
Bar-Ilan University study reveals disparity in quality of life among COVID-19 survivors from different ethnic groups
Bar-Ilan University

A new study conducted by researchers at Bar-Ilan University in Israel has shed light on the long-term impact of COVID-19 on the quality of life among different ethnic groups in the country. The study, part of a larger cohort project, highlights a significant discrepancy between Arabs and Druze, and Jews, with the two former groups experiencing a more pronounced decline in quality of life one year after infection.

   
Newswise: Pure capped mRNA vaccine opens the door to more effective vaccines with lower chances of inflammation
Released: 5-Jul-2023 12:40 PM EDT
Pure capped mRNA vaccine opens the door to more effective vaccines with lower chances of inflammation
Nagoya University

A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.

Newswise: A UCLA-led team has received a $925,000 CDC grant to track mpox outbreaks across the US
Released: 3-Jul-2023 8:00 AM EDT
A UCLA-led team has received a $925,000 CDC grant to track mpox outbreaks across the US
University of California, Los Angeles (UCLA), Health Sciences

A UCLA-led team has received $925,000 as part of a new grant from the Centers for Disease Control and Prevention (CDC) to conduct four surveillance projects tracking outbreaks of mpox--formerly known as monkeypox—across the U.S.

Newswise: June Research Highlights
Released: 30-Jun-2023 2:45 PM EDT
June Research Highlights
Cedars-Sinai

A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for June 2023.

Newswise: COVID-19 Vaccination Reduced Disease Disparities Between Low- and High-Income Communities
Released: 30-Jun-2023 11:05 AM EDT
COVID-19 Vaccination Reduced Disease Disparities Between Low- and High-Income Communities
Cedars-Sinai

COVID-19 vaccination helped reduce disparities in disease incidence between low- and high-income communities, according to a new analysis led by Cedars-Sinai investigators.

Newswise: Scientists Design a Nanoparticle That May Improve mRNA Cancer Vaccines
Released: 28-Jun-2023 9:30 AM EDT
Scientists Design a Nanoparticle That May Improve mRNA Cancer Vaccines
Johns Hopkins Medicine

Johns Hopkins Medicine scientists say they have developed a nanoparticle — an extremely tiny biodegradable container — that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.

Newswise: COVID-19 Vaccines Produce Antibody Response in the Nasal Mucosa
Released: 27-Jun-2023 9:40 AM EDT
COVID-19 Vaccines Produce Antibody Response in the Nasal Mucosa
University of North Carolina School of Medicine

A new study by researchers in the UNC School of Medicine, including Meghan Rebuli, PhD, Ilona Jaspers, PhD, and Kevin T. Cao, lead author, has found that SARS-CoV-2 mRNA vaccination induces an immune response in the mucosal lining of the nasal cavity, offering new insights into potential vaccine strategies in the future.

Released: 23-Jun-2023 3:05 PM EDT
Mpox Vaccine Trial for Adolescents, Children Begins at UM School of Medicine
University of Maryland School of Medicine

A 2022 outbreak of mpox (formerly monkeypox) sickened more than 30,000 people and caused 38 deaths in the United States. It highlighted the lack of an approved vaccine for those under 18 years old.

Released: 21-Jun-2023 2:10 PM EDT
Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens for enhanced protection
Science China Press

A team of researchers from the Chinese Academy of Sciences, the Chinese Academy of Agricultural Sciences, and Beijing Institute of Pharmacology and Toxicology have made significant progress in developing multi-valent mRNA vaccines against monkeypox virus (MPV), the agent that can cause smallpox-like disease in humans.

Released: 15-Jun-2023 12:55 PM EDT
In a first, researchers image adaptive immune systems at work in fish
University of Wisconsin–Madison

A new study from researchers at the University of Wisconsin–Madison offers a first-of-its-kind visual of a non-mammal species' adaptive immune system in action. The advance holds potential implications for a range of scientific aims, from improving wildlife vaccines to better understanding fundamental disease processes and possibly the evolution of adaptive immunity itself.

Released: 13-Jun-2023 2:55 PM EDT
CHOP Researchers Develop Universal MHC Molecules that Can be Produced Rapidly at Scale
Children's Hospital of Philadelphia

Researchers from Children’s Hospital of Philadelphia (CHOP) have engineered stable, universal MHC-I molecules that can be produced rapidly at scale, allowing researchers not only to develop vaccines and immunotherapies more quickly but also to identify molecules that can work broadly across the population. The findings were published today in the Proceedings of the National Academy of Sciences.

Released: 6-Jun-2023 3:05 PM EDT
COVID-19 vaccination: No serious side effects in young children
Kaiser Permanente

A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects.

Newswise:Video Embedded study-counter-stereotypical-messaging-can-move-needle-on-vaccinations
VIDEO
Released: 6-Jun-2023 2:55 PM EDT
Study: ‘Counter-stereotypical’ messaging can move needle on vaccinations
Washington University in St. Louis

New Olin Business School research demonstrates the effectiveness of partisan cues in a COVID-19 vaccination video ad campaign.A large-scale study to see if politically partisan cues can induce people to get COVID-19 vaccines found that, yes, they can.

Released: 6-Jun-2023 12:20 PM EDT
Husker scientists closing in on long-lasting swine flu vaccine
University of Nebraska-Lincoln

A successful long-term experiment with live hogs indicates Nebraska scientists may be another step closer to achieving a safe, long-lasting and potentially universal vaccine against swine flu.

   
Newswise: Family resemblance: How T cells could fight many coronaviruses at once
Released: 1-Jun-2023 3:00 PM EDT
Family resemblance: How T cells could fight many coronaviruses at once
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology show that T cells can recognize several different viral targets, called "antigens," shared between most coronaviruses, including common cold coronaviruses and SARS-CoV-2. They also looked more in-depth at what fragments of these antigens, called “epitopes,” are recognized and how conserved they are across different coronaviruses.

Released: 1-Jun-2023 1:40 PM EDT
Tip Sheet: First-in-human HIV vaccine results, progress in pediatric AML — and Fred Hutch at ASCO
Fred Hutchinson Cancer Center

Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the American Society for Clinical Oncology’s annual meeting, June 2-6 in Chicago, Illinois, see our list of Fred Hutch research highlights at ASCO and contact [email protected] to set up interviews with experts.

Newswise: Researchers Use ‘Natural’ System to Identify Proteins Most Useful For Developing an Effective HIV Vaccine
Released: 30-May-2023 2:00 PM EDT
Researchers Use ‘Natural’ System to Identify Proteins Most Useful For Developing an Effective HIV Vaccine
Johns Hopkins Medicine

Scientists have spent years trying to develop an effective HIV vaccine, but none have proven successful. Based on findings from a recently published study, a Johns Hopkins Medicine-led research team may have put science one step closer to that goal.

Released: 30-May-2023 12:05 PM EDT
People coinfected with SARS-CoV-2 and cytomegalovirus are at increased risk of developing cardiovascular disease
University of Cordoba

Cytomegalovirus (CMV) is one of the most prevalent herpesviruses worldwide. Depending on the geographical area, it can affect between 40% and 90% of the population and, although it does not produce symptoms in healthy people, the control of this chronic infection requires constant work by the immune system, which is constantly fighting to keep it at bay.

Newswise:Video Embedded lji-led-team-wins-top-nucleate-honors-for-virus-vaccine-development-proposal
VIDEO
Released: 25-May-2023 3:05 PM EDT
LJI-led team wins top Nucleate honors for virus vaccine development proposal
La Jolla Institute for Immunology

A San Diego team, led by scientists at La Jolla Institute for Immunology (LJI), has won the top prizes in the Nucleate Activator competition. Out of 1,000 initial competitors, the LJI team advanced to the final four teams and swept all the prizes they entered for. Their winning research proposal outlines how scientists could stop dengue virus and Zika virus by developing sophisticated vaccines that activate both B cells and T cells.

   
Released: 24-May-2023 10:05 AM EDT
Study Shows Key Role for Human T Cells in the Control of Respiratory Syncytial Virus (RSV) Infection
University of North Carolina School of Medicine

A new study published in JCI Insight, led by Angela Wahl, PhD, Raymond Pickles, PhD, and J. Victor Garcia, PhD, with the International Center for the Advancement of Translational Science (ICATS), the Department of Microbiology and Immunology, and the Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine has shown that human T cells have an important role to play in controlling infection.

Newswise: Engineers create bacteria that can synthesize an unnatural amino acid
Released: 23-May-2023 4:20 PM EDT
Engineers create bacteria that can synthesize an unnatural amino acid
University of Delaware

University of Delaware researchers in the lab of Aditya Kunjapur, assistant professor in the College of Engineering’s Department of Chemical and Biomolecular Engineering, have engineered bacteria to synthesize an amino acid that contains a rare functional group that others have shown to have implications in the regulation of our immune system. The researchers also taught a single bacterial strain to create the amino acid and place it at specific sites within target proteins.

Released: 23-May-2023 2:30 PM EDT
Previous smallpox vaccine provides immunity to mpox
Karolinska Institute

During last year’s mpox outbreak, the virus spread for the first time outside Africa, causing over 85,000 cases of the disease to date. Men who have sex with men account for the most infections, with a marked skew towards the young.

Released: 23-May-2023 3:05 AM EDT
COVID-19 vaccination reduces mortality also in critically ill corona patients
University of Vienna

Previous studies have shown that the mortality rate of Corona patients hospitalized and requiring oxygen therapy is similar no matter if they are vaccinated or unvaccinated. An international research team led by David Gómez-Varela from the Department for Pharmaceutical Sciences at the University of Vienna has now disproved these findings in a comprehensive multicontinental analysis published in the high-impact Journal of Medical Virology: The number of deaths of hospitalized patients would have been 22% lower if all unvaccinated, oxygen-dependent individuals had been vaccinated.



close
1.87262